New drugs in the treatment of heart failure

Clinical and Experimental Pharmacology & Physiology
L Brown

Abstract

1. Current therapy of heart failure relies on diuretics, positive inotropic compounds and vasodilators. The short-term haemodynamic benefits, especially of the cAMP generators, may be compromised by long-term limitations leading to an increased mortality. In contrast, some vasodilators, especially angiotensin converting enzyme inhibitors, improve survival even in severe heart failure. 2. Modulation of Na(+)- or K(+)-channels and calcium sensitization are positive inotropic mechanisms whose promise in treatment of heart failure needs to be fully explored. 3. The introduction of vasodilator therapy has been a significant advance. Newer compounds act to inhibit the endogenous vasoconstrictors angiotensin II and endothelin, or to potentiate the endogenous vasodilators atrial natriuretic factor and nitric oxide. The full potential of these compounds is yet to be realised.

References

Aug 15, 1992·The American Journal of Cardiology·D ElsnerG A Riegger
Apr 1, 1991·Journal of Molecular and Cellular Cardiology·R H SchwingerE Erdmann
Aug 11, 1991·Naunyn-Schmiedeberg's Archives of Pharmacology·L BrownJ R Bourke
Jun 1, 1991·American Heart Journal·C V Leier, P F Binkley
Apr 1, 1990·Circulation Research·H UrataA Husain
Jul 1, 1986·Cardiovascular Research·L BrownE Erdmann
Jan 1, 1988·Naunyn-Schmiedeberg's Archives of Pharmacology·M NäbauerE Erdmann
Dec 1, 1988·European Journal of Clinical Investigation·M NäbauerE Erdmann
Feb 1, 1994·American Journal of Respiratory and Critical Care Medicine·B GastonJ S Stamler
Oct 1, 1994·Journal of Cardiovascular Pharmacology·R NankervisL Brown
Oct 1, 1993·Journal of the American College of Cardiology·A M Feldman
Oct 1, 1994·Clinical and Experimental Pharmacology & Physiology·L Brown, C Sernia
Nov 1, 1994·Clinical and Experimental Pharmacology & Physiology·S DoggrellL Brown
Dec 1, 1993·Circulation·P W Armstrong, G W Moe
Jul 1, 1994·Circulation Research·S K Mishra, K Hermsmeyer
Jan 1, 1994·Cardiovascular Research·J B WarrenA J Brady
Nov 1, 1993·Pharmacology & Toxicology·E HayesM J Walker
Apr 1, 1994·Circulation·C M WeiJ C Burnett
Aug 1, 1993·Cardiovascular Drugs and Therapy·J M Cruickshank
Oct 1, 1993·Journal of the American College of Cardiology·U ElkayamE Ostrzega
Oct 1, 1993·Journal of the American College of Cardiology·K K HoD Levy
Oct 1, 1993·Journal of the American College of Cardiology·M Packer
Jan 1, 1993·Circulation·W J ManningR R Edelman
May 1, 1993·American Journal of Hypertension·I KobrinV Charlon
Jul 15, 1993·The New England Journal of Medicine·A M FeldmanR P Bain

❮ Previous
Next ❯

Citations

Oct 1, 1996·Toxicon : Official Journal of the International Society on Toxinology·T L AceretP W Sammarco
Feb 1, 1997·Transplantation Proceedings·R Shapiro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.